“The simplSEQ workflow offers many workflow advantages over other methods of cell-free DNA extraction especially speed, simplicity, reproducibility, which are

Company Filed Second Patent Application to Extend Core Technology Applications



Murrieta Genomics is pleased to announce that U.S. Patent and Trademark

Murrieta Genomics, the launch pad for genomic sequencing startups, is pleased to announce that simplSEQ, an incubator company and subsidiary,

“Our first product is a kit for the purification and isolation of nucleic acids from plasma that we believe will

“The simplSEQ workflow offers many workflow advantages over other methods of cell-free DNA extraction especially speed, simplicity, reproducibility, which are

Company Filed Second Patent Application to Extend Core Technology Applications



Murrieta Genomics is pleased to announce that U.S. Patent and Trademark

Murrieta Genomics, the launch pad for genomic sequencing startups, is pleased to announce that simplSEQ, an incubator company and subsidiary,

“Our first product is a kit for the purification and isolation of nucleic acids from plasma that we believe will

On Friday, January 29th 2021 an article about Murrieta Genomics and our wholly owned subsidiary, SimplSEQ, was published by GenomeWeb.

The RuleOut team has created a novel approach that can exponentially increase COVID-19 testing capacity.

Life Science Nation provides an incredibly important service to early stage life science companies by connecting them with products, services

John Powers, President of Murrieta Genomics and CEO of SimplSeq, our wholly owned subsidiary, was interviewed recently on Beyone with